Glenmark Pharmaceuticals to launch DCGI-approved BRUKINSA in India for treatment of hematological malignancies

Globally, BRUKINSA is approved in more than 70 countries

AstraZeneca’s fixed-duration Calquence-based regimens approved in EU for patients with chronic lymphocytic leukaemia

AMPLIFY Phase III trial results demonstrated statistically significant and clinically meaningful improvement in progression-free survival for Calquence combinations

New Reverse Osmosis pure water dialysis system unveiled by NIPRO at ERA 2025

Ichnos Glenmark Innovation’s full dose-escalation data show high response rates of ISB 2001

AstraZeneca's enhertu improved pCR in early-stage breast cancer

AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety profile vs. standard of care

USFDA inspects Marksans’s subsidiary Time-Cap Laboratories' manufacturing facility

The Subsidiary has received one inspectional observation in Form 483

Gujarat CM Bhupendra Patel inaugurates 217-bed cancer hospital in Ahmedabad

The new facility combines advanced technology, enhanced capacity, and holistic care, reaffirming HCG’s commitment to accessible, world-class oncology in Gujarat

AstraZeneca, Daiichi Sankyo announce Enhertu plus pertuzumab demonstrated clinically meaningful improvement as 1st-line therapy for patients with metastatic breast cancer

DESTINY-Breast09 Phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2-positive metastatic patient population versus current 1st-line standard of care

GSK’s blenrep combinations approved by UK MHRA in relapsed/refractory multiple myeloma

Blenrep combinations could redefine treatment as early as first relapse where more effective options are needed

AstraZeneca’s Imfinzi-based perioperative regimen approved in EU for resectable non-small cell lung cancer

Approval based on AEGEAN Phase III trial results which showed a 32% reduction in the risk of recurrence, progression or death vs. neoadjuvant chemotherapy alone